



Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BM/BSE

Date : 26.07.2022

BSE Limited,  
Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai- 400 001  
Company Code- 541400

Dear Sir,

Sub : **Outcome of Board Meeting held on 26.07.2022**

This is to inform you that the Board of Directors at its meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended 30.06.2022. Copy of unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiook & Co LLP, Statutory Auditors of the Company is enclosed.

The Board Meeting commenced at 03:00 p.m. and concluded at 06:00 p.m.

Thanking you,

Yours faithfully,  
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)  
Company Secretary and Compliance Officer



Encl : As above.

**ZIM LABORATORIES LIMITED**

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur  
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square  
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

---

**Walker Chandiook & Co LLP**

11th Floor, Tower II,  
One International Center,  
S B Marg, Prabhadevi (W),  
Mumbai - 400013  
Maharashtra, India  
T +91 22 6626 2699  
F +91 22 6626 2601

## **Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

### **To the Board of Directors of ZIM Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **ZIM Laboratories Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer note below for the list of subsidiaries included in the Statement) for the quarter ended **30 June 2022**, being submitted by the Holding Company, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

#### List of subsidiaries included in the Statement

1. ZIM Laboratories FZE
  2. ZIM Health Technologies Limited
  3. SIA ZIM Laboratories Limited
  4. ZIM Thinorals Private Limited
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

**ZIM Laboratories Limited**

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

**KHUSHROO**  
**B PANTHAKY**

Digitally signed by  
KHUSHROO B  
PANTHAKY  
Date: 2022.07.26  
17:07:53 +05'30'

**Khushroo B. Panthaky**

Partner

Membership No:042423

**UDIN:22042423ANPRRZ1960**

Place: Nagpur

Date: 26 July 2022



**ZIM Laboratories Limited**

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India  
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022**

(Rs. in lakhs, unless otherwise stated)

| Sr. No. | Particulars  | Quarter ended   |                             |                 | Year ended       |
|---------|--|-----------------|-----------------------------|-----------------|------------------|
|         |  | 30.06.2022      | 31.03.2022                  | 30.06.2021      | 31.03.2022       |
|         |  | (Unaudited)     | (Unaudited)<br>Refer Note 3 | (Unaudited)     | (Audited)        |
| 1       | <b>Income</b>  |                 |                             |                 |                  |
|         | a) Revenue from operations   | 9,274.55        | 10,506.44                   | 6,417.28        | 33,342.68        |
|         | b) Other income  | 189.47          | 162.65                      | 122.33          | 440.27           |
|         | <b>Total income</b>  | <b>9,464.02</b> | <b>10,669.09</b>            | <b>6,539.61</b> | <b>33,782.95</b> |
| 2       | <b>Expenses</b>  |                 |                             |                 |                  |
|         | a) Cost of materials consumed  | 3,889.08        | 5,487.77                    | 2,954.91        | 16,060.98        |
|         | b) Purchases of stock-in-trade   | 625.31          | 214.05                      | 6.02            | 940.64           |
|         | c) Changes in inventories of finished goods, stock-in-trade and work-in-progress     | 58.56           | (692.51)                    | 323.69          | (966.90)         |
|         | d) Employee benefits   | 1,222.74        | 1,114.21                    | 1,032.02        | 4,006.59         |
|         | e) Finance costs   | 133.12          | 143.11                      | 254.60          | 830.62           |
|         | f) Depreciation and amortisation   | 426.99          | 418.24                      | 366.02          | 1,603.31         |
|         | g) Other expenses  | 2,360.60        | 2,907.17                    | 1,573.49        | 9,203.46         |
|         | <b>Total expenses</b>  | <b>8,716.40</b> | <b>9,592.04</b>             | <b>6,510.75</b> | <b>31,678.70</b> |
| 3       | <b>Profit before tax (1-2)</b>   | <b>747.62</b>   | <b>1,077.05</b>             | <b>28.86</b>    | <b>2,104.25</b>  |
| 4       | <b>Tax expense</b>   |                 |                             |                 |                  |
|         | Current Tax  | 133.31          | 203.15                      | 3.07            | 354.12           |
|         | Deferred Tax   | 99.53           | 170.88                      | 6.92            | 295.09           |
|         | <b>Total tax expense</b>   | <b>232.84</b>   | <b>374.03</b>               | <b>9.99</b>     | <b>649.21</b>    |
| 5       | <b>Profit after tax (3-4)</b>  | <b>514.78</b>   | <b>703.02</b>               | <b>18.87</b>    | <b>1,455.04</b>  |
| 6       | <b>Other comprehensive income - profit/(loss)</b>                                    |                 |                             |                 |                  |
|         | a) Items that will not be reclassified to profit or loss                             | 1.61            | 47.18                       | (13.58)         | 6.44             |
|         | b) Tax (expense)/credit on the items that will not be reclassified to profit or loss | (0.47)          | (13.74)                     | 3.95            | (1.88)           |
|         | c) Items that may be reclassified to profit or loss                                  | 47.16           | 14.95                       | 12.57           | 36.35            |
|         | d) Tax (expense)/credit on the items that will be reclassified to profit or loss     | -               | -                           | -               | -                |
|         | <b>Other comprehensive income (net of tax) - profit/(loss)</b>                       | <b>48.30</b>    | <b>48.39</b>                | <b>2.94</b>     | <b>40.91</b>     |
| 7       | <b>Total comprehensive income (5+6)</b>  | <b>563.08</b>   | <b>751.41</b>               | <b>21.81</b>    | <b>1,495.95</b>  |
| 8       | Paid-up equity share capital (face value of Rs. 10/- each)                           | 1,624.19        | 1,624.19                    | 1,624.19        | 1,624.19         |
| 9       | Other equity (revaluation reserve : Rs. Nil)   |                 |                             |                 | 15,946.76        |
| 10      | Earnings per share (face value of Rs. 10/- each) (not annualised) (Rs.)              |                 |                             |                 |                  |
|         | Basic  | 3.17            | 4.33                        | 0.12            | 8.96             |
|         | Diluted  | 3.17            | 4.33                        | 0.12            | 8.96             |

**Notes :**

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26 July 2022. There are no qualifications in the limited review report issued for the quarter ended 30 June 2022.
- 2) These financial results have been prepared in accordance with the Indian Accounting Standards as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 ('Act') and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The figures for the quarter ended 31 March 2022 are the balancing figures between the audited figures for the year ended 31 March 2022 and the unaudited year to date figures upto 31 December 2021, on which auditors had performed a limited review.
- 4) The Company and its subsidiaries are principally engaged in a single business segment which is "pharmaceuticals".

**Place: Nagpur**  
**Date: 26 July 2022**

**ANWAR  
DAUD**

Digital signed by ANWAR DAUD  
DN: cn=ANWAR DAUD, o=ANWAR DAUD, email=ANWAR.DAUD@ANWAR.DAUD.COM, c=IN  
Reason: I am the Signer  
Anwar Daud - 25/07/2022 10:48:15 AM  
Date: 2022.07.26 10:48:15 AM

**Anwar S. Daud**  
**Managing Director**

---

**Walker Chandiook & Co LLP**

11th Floor, Tower II,  
One International Center,  
S B Marg, Prabhadevi (W),  
Mumbai - 400013  
Maharashtra, India  
T +91 22 6626 2699  
F +91 22 6626 2601

## **Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

### **To the Board of Directors of ZIM Laboratories Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **ZIM Laboratories Limited** ('the Company') for the quarter ended **30 June 2022**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**ZIM Laboratories Limited**

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Walker Chandio & Co LLP**  
Chartered Accountants  
Firm Registration No:001076N/N500013

**KHUSHROO** Digitally signed by  
**B PANTHAKY** KHUSHROO B PANTHAKY  
Date: 2022.07.26 17:08:28  
+05'30'

**Khushroo B. Panthaky**  
Partner  
Membership No:042423

**UDIN:22042423ANPRKY4103**

Place: Nagpur  
Date: 26 July 2022



**ZIM Laboratories Limited**

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India

CIN:L99999MH1984PLC032172, Website: www.zimlab.in

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022**

(Rs. in lakhs, unless otherwise stated)

| Sr. No. | Particulars  | Quarter ended   |                             |                 | Year ended       |
|---------|--|-----------------|-----------------------------|-----------------|------------------|
|         |  | 30.06.2022      | 31.03.2022                  | 30.06.2021      | 31.03.2022       |
|         |  | (Unaudited)     | (Unaudited)<br>Refer Note 3 | (Unaudited)     | (Audited)        |
| 1       | <b>Income</b>  |                 |                             |                 |                  |
|         | a) Revenue from operations   | 9,250.30        | 10,410.82                   | 6,363.96        | 32,949.37        |
|         | b) Other income  | 187.32          | 164.70                      | 125.09          | 450.62           |
|         | <b>Total income</b>  | <b>9,437.62</b> | <b>10,575.52</b>            | <b>6,489.05</b> | <b>33,399.99</b> |
| 2       | <b>Expenses</b>  |                 |                             |                 |                  |
|         | a) Cost of materials consumed  | 3,889.08        | 5,487.77                    | 2,954.91        | 16,060.98        |
|         | b) Purchases of stock-in-trade   | 625.31          | 214.05                      | 6.02            | 940.64           |
|         | c) Changes in inventories of finished goods, stock-in-trade and work-in-progress     | 58.56           | (692.51)                    | 323.69          | (966.90)         |
|         | d) Employee benefits   | 1,110.42        | 1,067.07                    | 1,000.00        | 3,863.28         |
|         | e) Finance costs   | 133.12          | 143.11                      | 254.60          | 830.62           |
|         | f) Depreciation and amortisation   | 395.08          | 387.73                      | 336.42          | 1,483.74         |
|         | g) Other expenses  | 2,428.99        | 2,966.35                    | 1,586.47        | 9,257.97         |
|         | <b>Total expenses</b>  | <b>8,640.56</b> | <b>9,573.57</b>             | <b>6,462.11</b> | <b>31,470.33</b> |
| 3       | <b>Profit before tax (1-2)</b>   | <b>797.06</b>   | <b>1,001.95</b>             | <b>26.94</b>    | <b>1,929.66</b>  |
| 4       | <b>Tax expense/ (credit)</b>   |                 |                             |                 |                  |
|         | Current Tax  | 133.31          | 191.89                      | 2.08            | 340.02           |
|         | Deferred Tax   | 99.53           | 166.04                      | 6.27            | 288.36           |
|         | <b>Total tax expense / (credit)</b>  | <b>232.84</b>   | <b>357.93</b>               | <b>8.35</b>     | <b>628.38</b>    |
| 5       | <b>Profit after tax (3-4)</b>  | <b>564.22</b>   | <b>644.02</b>               | <b>18.59</b>    | <b>1,301.28</b>  |
| 6       | <b>Other comprehensive income - profit/(loss)</b>                                    |                 |                             |                 |                  |
|         | a) Items that will not be reclassified to profit or loss                             | 1.61            | 47.18                       | (13.58)         | 6.44             |
|         | b) Tax (expense)/credit on the items that will not be reclassified to profit or loss | (0.47)          | (13.74)                     | 3.95            | (1.88)           |
|         | <b>Other comprehensive income (net of tax) - profit/(loss)</b>                       | <b>1.14</b>     | <b>33.44</b>                | <b>(9.63)</b>   | <b>4.56</b>      |
| 7       | <b>Total comprehensive income (5+6)</b>  | <b>565.36</b>   | <b>677.46</b>               | <b>8.96</b>     | <b>1,305.84</b>  |
| 8       | Paid-up equity share capital (face value of Rs. 10/- each)                           | 1,624.19        | 1,624.19                    | 1,624.19        | 1,624.19         |
| 9       | Other equity (revaluation reserve : Rs. Nil)   |                 |                             |                 | 15,386.41        |
| 10      | Earnings per share (face value of Rs. 10/- each) (not annualised) (Rs.)              |                 |                             |                 |                  |
|         | Basic  | 3.47            | 3.96                        | 0.11            | 8.01             |
|         | Diluted  | 3.47            | 3.96                        | 0.11            | 8.01             |



**Notes :**

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26 July 2022. There are no qualifications in the limited review report issued for the quarter ended 30 June 2022.
- 2) These financial results have been prepared in accordance with the Indian Accounting Standards as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 ('Act') and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The figures for the quarter ended 31 March 2022 are the balancing figures between the audited figures for the year ended 31 March 2022 and the unaudited year to date figures upto 31 December 2021, on which auditors had performed a limited review.
- 4) The Company is principally engaged in a single business segment which is "pharmaceuticals".

**Place: Nagpur**  
**Date: 26 July 2022**

**ANWAR  
DAUD**

Digitally signed by ANWAR DAUD  
DN: cn=ANWAR DAUD, o=ANWAR DAUD, email=anwar@anwarindia.com, c=IN  
Reason: I am the signer of this document.  
MD5Digest: SHA-256 with RSA Encryption  
Date: 2022.07.26 16:09:51 +05'30

**Anwar S. Daud**  
**Managing Director**